Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-121 as Adjunctive Treatment for Major Depressive Disorder
NCT03093025Phase 2Terminated
- Sponsor
- Taisho Pharmaceutical
- Start
- Jul 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ANC-501 in major depressive disorder (MDD), sponsored by Taisho Pharmaceutical. Started Jul 2017; status: terminated.
02
Drugs
ANC-501
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03093025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093025.